After gapping down, Qualigen Therapeutics Inc (NASDAQ:QLGN) is seeing buying action at lower level.
As of 9:59, QLGN stock is trading lower by 5.43% or $0.10 to $1.72. So far 128K shares have exchanged hands. The stock opened at $1.72 and moved in a range of 1.6300 – 1.7400.
QLGN Issues News This Morning
Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer
- QLGN announced the appointment of Tariq Arshad, MD, MBA to the newly-created position of Senior Vice President, Chief Medical Officer.
- Dr. Arshad brings more than 20 years of biotech and pharmaceutical experience to Qualigen Therapeutics during a dynamic time of growth and implementation of long-range strategy.
- Dr. Arshad is an oncologist with expertise in both early and late stage clinical development at several leading and emergent biopharmaceutical companies, including leadership roles at Becton Dickinson, Sanofi Genzyme, Humanigen, XOMA, Merck, Genentech, and Pfizer.
- Most recently, Dr. Arshad was Global Head of Medical Affairs and Clinical Research for Becton Dickinson BioSciences in San Jose, California where he led a team of MDs and PhDs driving scientific strategy for a cutting-edge immuno-oncology focused portfolio.
“We are delighted to welcome Tariq to Qualigen as our Chief Medical Officer during this exciting time where he will serve in a mission-critical role as we advance our oncology and viral disease pipeline programs,” stated Michael Poirier, Chairman and Chief Executive Officer at Qualigen Therapeutics.
Dr. Arshad commented, “I am thrilled to join a dedicated team with a calling to develop therapeutics for patients with few treatment options. I plan to apply my expertise in immuno-oncology and clinical development to help solve the medical problems that devastate patients who suffer from these conditions.”